Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Oil & Gas, Basic Materials and Technology sectors led shares lower. At the close in NYSE, the...
Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Basic Materials, Telecoms and Oil & Gas sectors led shares higher while losses in the Technology,...
Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Telecoms, Technology and Oil & Gas sectors led shares lower. At the close in NYSE, the Dow Jones...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Buy | Buy | Strong Sell | Strong Sell | Neutral |
| Summary | Neutral | Neutral | Strong Sell | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,660.30 | 2,668.00 | 2,596.00 | +91.9 | +3.58% | 2.08M | NASDAQ | |||
| 369.79 | 375.33 | 357.19 | +18.60 | +5.30% | 33.69M | NASDAQ | |||
| 9.98 | 9.98 | 9.96 | +0.010 | +0.10% | 53.52K | NASDAQ | |||
| 75.94 | 76.04 | 74.89 | +0.41 | +0.54% | 12.35M | NASDAQ | |||
| 3.20 | 3.39 | 3.13 | -0.040 | -1.23% | 14.27K | NASDAQ | |||
| 4.64 | 4.857 | 4.415 | +0.040 | +0.87% | 49.72K | NASDAQ | |||
| 124.62 | 130.73 | 116.16 | -10.06 | -7.47% | 8.68M | NASDAQ | |||
| 36.81 | 36.87 | 36.27 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 7.00 | 7.10 | 6.39 | 0.00 | 0.00% | 13.60K | NASDAQ | |||
| 42.52 | 43.38 | 42.48 | -0.13 | -0.30% | 291.17K | NYSE | |||
| 0.7299 | 0.00 | 0.00 | -0.0801 | -9.89% | 1.73M | NASDAQ | |||
| 195.58 | 197.00 | 192.50 | -0.36 | -0.18% | 19.57M | NASDAQ | |||
| 46.51 | 47.20 | 46.12 | +0.60 | +1.31% | 5.03M | NYSE | |||
| 55.34 | 56.28 | 54.73 | -0.90 | -1.60% | 10.62M | NYSE | |||
| 57.01 | 57.33 | 56.45 | +0.54 | +0.96% | 12.14M | NYSE |
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.
